Recommended Topic Related To:

Skyla

"Oct. 18, 2012 -- While the use of long-acting intrauterine devices (IUDs) is increasing, 1 in 9 women at risk for unintended pregnancies is not using any birth control, according to a new government report.

Researchers from the Natio"...

Skyla

Side Effects
Interactions

SIDE EFFECTS

The following serious or otherwise important adverse reactions are discussed elsewhere in the labeling:

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The data described below reflect exposure to Skyla in 1,672 patients in two contraception studies, including 1,383 exposed for one year and 993 who completed the three year studies. The population was generally healthy, 18 to 40-year old females requesting contraception and predominately Caucasian (82.6%). The data cover more than 40,000 cycles of exposure. The frequencies of reported adverse drug reactions represent crude incidences.

Most common adverse reactions (occurring in ≥ 5% users) were increased bleeding (7.8%), vulvovaginitis (20.2%), abdominal/pelvic pain (18.9%), acne/seborrhea (15.0%), ovarian cyst (13.2%), headache (12.4%), dysmenorrhea (8.6%), breast pain/discomfort (8.6%) and nausea (5.5%).

In the contraception studies, 18% discontinued prematurely due to an adverse reaction. The most common adverse reactions leading to discontinuation (in > 1% of users) were uterine bleeding complaints (4.6%), device expulsion (3.2%), acne/seborrhea (2.9%), abdominal pain (2.5%) dysmenorrhea/uterine spasms (2.0%) and pelvic pain (1.8%).

Other common adverse reactions (occurring in ≥ 1% users) by System Organ Class (SOC): The frequencies of adverse reactions observed in clinical trials are summarized in Table 3 by SOC (presented as crude incidences).

Table 3: Adverse reactions that occurred in at least 1% of Skyla users in clinical trials by SOC

System Organ Class Adverse Reaction Incidence (%)
(N=1,672)
Reproductive System and Breast Disorders Vulvovaginitis 20.2
Ovarian cysta 13.2
Dysmenorrhoea 8.6
Increased bleeding b 7.8
Breast pain/discomfort 5.3/3.3
Genital discharge 4.2
Device expulsion (complete and partial) 3.2
Upper genital tract infection 1.4
Gastrointestinal Disorders Abdominal pain/pelvic pain 12.7/6.2
Nausea 5.5
Skin and Subcutaneous Tissue Disorders Acne/Seborrhoea 13.6/1.4
Alopecia 1.2
Nervous System Disorders Headache 12.4
Migraine 2.3
Psychiatric Disorders Depression/ Depressed mood 3.8/0.5
aOvarian cysts were reported as AEs if they were abnormal, non-functional cysts and/or had a diameter > 3 cm on ultrasound examination
bNot all bleeding alterations were captured as adverse reactions [see WARNINGS AND PRECAUTIONS].

Postmarketing Experience

The following adverse reactions have been identified during post approval use of another LNG IUS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Read the Skyla (levonorgestrel-releasing intrauterine system) Side Effects Center for a complete guide to possible side effects

DRUG INTERACTIONS

No drug-drug interaction studies have been conducted with Skyla.

Drugs or herbal products that induce enzymes, including CYP3A4, that metabolize progestins may decrease the serum concentrations of progestins.

Some drugs or herbal products that may decrease the serum concentration of LNG include:

  • Barbiturates
  • Bosentan
  • Carbamazepine
  • Efavirenz
  • Felbamate
  • Griseofulvin
  • Nevirapine
  • Oxcarbazepine
  • Phenytoin
  • Rifabutin
  • Rifampin
  • St. John's wort
  • Topiramate

Significant changes (increase or decrease) in the serum concentrations of the progestin have been noted in some cases of co-administration with HIV protease inhibitors or with non-nucleoside reverse transcriptase inhibitors. CYP3A4 inhibitors such as itraconazole or ketoconazole may increase plasma hormone levels.

Consult the labeling of all concurrently used drugs to obtain further information about interactions with Skyla or the potential for enzyme alterations.

Last reviewed on RxList: 10/10/2013
This monograph has been modified to include the generic and brand name in many instances.

Side Effects
Interactions
A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.